TriSalus Life Sciences (NASDAQ:TLSI) CEO Mary Szela Purchases 39,682 Shares

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary Szela bought 39,682 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The stock was purchased at an average cost of $2.59 per share, for a total transaction of $102,776.38. Following the transaction, the chief executive officer owned 1,065,215 shares in the company, valued at $2,758,906.85. The trade was a 3.87% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

TriSalus Life Sciences Stock Up 13.1%

Shares of TriSalus Life Sciences stock opened at $3.03 on Tuesday. The business’s 50 day simple moving average is $4.14 and its 200 day simple moving average is $5.11. TriSalus Life Sciences, Inc. has a 52-week low of $2.20 and a 52-week high of $7.95. The firm has a market cap of $185.77 million, a PE ratio of -2.15 and a beta of 0.56. The company has a debt-to-equity ratio of 2.58, a quick ratio of 5.46 and a current ratio of 5.78.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. The firm had revenue of $13.21 million during the quarter, compared to analyst estimates of $13.20 million. On average, analysts predict that TriSalus Life Sciences, Inc. will post -0.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on TLSI shares. Canaccord Genuity Group lowered their price target on TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, March 6th. Lake Street Capital lowered their price target on TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. Weiss Ratings lowered TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 13th. Finally, Wall Street Zen raised TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, TriSalus Life Sciences has a consensus rating of “Hold” and a consensus target price of $7.50.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. increased its holdings in shares of TriSalus Life Sciences by 35,804.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock worth $41,000 after acquiring an additional 7,519 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of TriSalus Life Sciences during the 2nd quarter worth approximately $47,000. Invesco Ltd. acquired a new position in shares of TriSalus Life Sciences during the 4th quarter worth approximately $72,000. Abel Hall LLC acquired a new position in shares of TriSalus Life Sciences during the 4th quarter worth approximately $73,000. Finally, HighMark Wealth Management LLC acquired a new position in shares of TriSalus Life Sciences during the 4th quarter worth approximately $75,000. Institutional investors and hedge funds own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.